These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18988884)

  • 1. Regression of HIV-related diffuse large B-cell lymphoma in response to antiviral therapy alone.
    Amengual JE; Zhang X; Ibrahim S; Gardner LB
    Blood; 2008 Nov; 112(10):4359-60. PubMed ID: 18988884
    [No Abstract]   [Full Text] [Related]  

  • 2. No changes in efavirenz plasma concentrations in HIV-infected patients who switch from Stocrin to Atripla.
    Burger D; van Luin M; Bosch M; van der Ven A; Brouwer AM; Keuter M; Dofferhoff T; Koopmans PP
    J Acquir Immune Defic Syndr; 2010 Aug; 54(5):e12-3. PubMed ID: 20647821
    [No Abstract]   [Full Text] [Related]  

  • 3. [HIV therapy and adherence].
    Kuhlmann B
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():62-3. PubMed ID: 19024920
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent FDA approvals and changes.
    AIDS Patient Care STDS; 2010 Feb; 24(2):133-4. PubMed ID: 20156092
    [No Abstract]   [Full Text] [Related]  

  • 5. Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients.
    Calza L; Vanino E; Salvadori C; Manfredi R; Colangeli V; Cascavilla A; Di Bari MA; Motta R; Viale P
    HIV Clin Trials; 2014; 15(1):1-13. PubMed ID: 24518210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?
    Goicoechea M; Best B
    Expert Opin Pharmacother; 2007 Feb; 8(3):371-82. PubMed ID: 17266471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
    Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
    [No Abstract]   [Full Text] [Related]  

  • 8. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
    Rockstroh JK; DeJesus E; Lennox JL; Yazdanpanah Y; Saag MS; Wan H; Rodgers AJ; Walker ML; Miller M; DiNubile MJ; Nguyen BY; Teppler H; Leavitt R; Sklar P;
    J Acquir Immune Defic Syndr; 2013 May; 63(1):77-85. PubMed ID: 23412015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emtricitabine/tenofovir disoproxil fumarate.
    Drugs R D; 2004; 5(3):160-1. PubMed ID: 15139777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-tablet Quad regimen achieves high rate of virologic suppression.
    AIDS Patient Care STDS; 2010 Mar; 24(3):197. PubMed ID: 20214488
    [No Abstract]   [Full Text] [Related]  

  • 11. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
    Pozniak AL; Gallant JE; DeJesus E; Arribas JR; Gazzard B; Campo RE; Chen SS; McColl D; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):535-40. PubMed ID: 17057609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet.
    Frampton JE; Croom KF
    Drugs; 2006; 66(11):1501-12; discussion 1513-4. PubMed ID: 16906786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.
    Gazzard BG
    Expert Opin Pharmacother; 2006 Apr; 7(6):793-802. PubMed ID: 16556093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA paves the way for pre-exposure HIV prophylaxis.
    Holmes D
    Lancet; 2012 Jul; 380(9839):325. PubMed ID: 22852138
    [No Abstract]   [Full Text] [Related]  

  • 15. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of adherence and efficiency when replacing an antiretroviral therapy with efavirenz-emtricitabine-tenofovir in a single daily dose].
    García-Ramos SE; Santolaya Perrín MR; Fernández-Pacheco García-Valdecasas M
    Farm Hosp; 2012; 36(5):315-20. PubMed ID: 22858089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic aspects of new antiretroviral drugs.
    Long MC; King JR; Acosta EP
    Curr HIV/AIDS Rep; 2009 Feb; 6(1):43-50. PubMed ID: 19149996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collaboration begins on combined drug.
    AIDS Patient Care STDS; 2005 Feb; 19(2):129. PubMed ID: 15747431
    [No Abstract]   [Full Text] [Related]  

  • 19. A once-daily combination tablet (Atripla) for HIV.
    Med Lett Drugs Ther; 2006 Sep; 48(1244):78-9. PubMed ID: 17001298
    [No Abstract]   [Full Text] [Related]  

  • 20. [Efavirenz in fixed combination with tenofovir and emtricitabine. Long-term effectiveness verified in new studies].
    Wepner U
    MMW Fortschr Med; 2011 May; 153(18):20-1. PubMed ID: 21604586
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.